Amoxicillin and Metronidazole

ApprovedSmall molecule

Amoxicillin and Metronidazole is one of 26 small molecule programs targeting Periodontitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PeriodontitisActive, not recruiting

Aggressive PeriodontitisActive, not recruiting

PeriodontitisApproved

Active, not recruiting

Aggressive PeriodontitisApproved

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Periodontitis

#DrugCompanyPhaseTrials

Peridex

DDexcel Pharma Technologies Ltd.

Phase 3

10 2

Acanya

Pfizer

Phase 3

1 3

Curcumin

Merck & Co.

Phase 3

1 4

Bayer Aspirin

Bayer

Phase 2

1 5

Calcium Hydroxide

MMansoura University

Phase 3

2 6

Amoxicillin and Metronidazole

UUniversity of Campinas, Brazil

Approved

1 7

Calcium Intravenous Infsuion

MMansoura University

Phase 3

2 8

Minocycline Hcl

OOraPharma

Phase 3

1 9

Boswellia

MMansoura University

Phase 3

1 10

Metapex

AAga Khan University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Periodontitis1 trial

Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization

Completed·UUniversity Hospital Muenster·Phase 4·NCT00707369·540 enrolled

Aggressive Periodontitis1 trial

Amoxicillin and Metronidazole in Association With Non-surgical Therapy in Aggressive Periodontitis Treatment

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT03933501·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Amoxicillin and Metronidazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amoxicillin and Metronidazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amoxicillin and Metronidazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Campinas, Brazil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Campinas, Brazil

Amoxicillin and Metronidazole

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Periodontitis1 trial

Aggressive Periodontitis1 trial

References

Drug Info

Quick Facts

Related News